CN103717609B - 聚(adp-核糖)聚合酶的三环抑制剂 - Google Patents

聚(adp-核糖)聚合酶的三环抑制剂 Download PDF

Info

Publication number
CN103717609B
CN103717609B CN201280024255.0A CN201280024255A CN103717609B CN 103717609 B CN103717609 B CN 103717609B CN 201280024255 A CN201280024255 A CN 201280024255A CN 103717609 B CN103717609 B CN 103717609B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
oxo
azaphosphorin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280024255.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103717609A (zh
Inventor
沈旺
杰克·满
张爱民
郑晓玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Kanion Pharmaceutical Co Ltd
Original Assignee
Jiangsu Kanion Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Kanion Pharmaceutical Co Ltd filed Critical Jiangsu Kanion Pharmaceutical Co Ltd
Publication of CN103717609A publication Critical patent/CN103717609A/zh
Application granted granted Critical
Publication of CN103717609B publication Critical patent/CN103717609B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280024255.0A 2011-05-31 2012-05-31 聚(adp-核糖)聚合酶的三环抑制剂 Active CN103717609B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161491851P 2011-05-31 2011-05-31
US61/491,851 2011-05-31
PCT/US2012/040304 WO2012166983A1 (en) 2011-05-31 2012-05-31 Tricyclic inhibitors of poly(adp-ribose)polymerase

Publications (2)

Publication Number Publication Date
CN103717609A CN103717609A (zh) 2014-04-09
CN103717609B true CN103717609B (zh) 2016-05-11

Family

ID=47259874

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280024255.0A Active CN103717609B (zh) 2011-05-31 2012-05-31 聚(adp-核糖)聚合酶的三环抑制剂

Country Status (8)

Country Link
US (4) US20140221314A1 (https=)
EP (2) EP2714703B1 (https=)
JP (1) JP5960253B2 (https=)
CN (1) CN103717609B (https=)
CA (1) CA2875025C (https=)
ES (1) ES2871052T3 (https=)
TW (1) TWI577693B (https=)
WO (1) WO2012166983A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2714703B1 (en) 2011-05-31 2021-03-10 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
PL2938598T3 (pl) 2012-12-31 2017-05-31 Cadila Healthcare Limited Podstawione pochodne ftalazyn-1 (2H)-onu jako selektywne inhibitory polimerazy-1 poli(ADP-rybozy)
US10562886B2 (en) 2015-05-21 2020-02-18 The Regents Of The University Of California Anti-cancer compounds
HUE066216T2 (hu) 2016-06-24 2024-07-28 Univ California Ftalazin származékok, mint a parp1, parp2 és/vagy tubulin inhibitorai, hasznosak a rák kezelésében
CA3095709A1 (en) * 2018-04-05 2019-10-10 Noviga Research Ab Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
EP4013749B1 (en) 2019-08-15 2026-03-11 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
CN112574122B (zh) * 2019-09-27 2024-05-31 上海天慈国际药业有限公司 一种奥拉帕尼关键中间体的制备方法
CN114276301B (zh) * 2020-09-27 2025-04-01 江西科睿药业有限公司 Parp抑制剂的中间体化合物及其制备方法和应用
CN112624981B (zh) * 2021-03-09 2021-05-25 南京桦冠生物技术有限公司 一种2-氟-5-[(4-氧代-3h-2,3-二氮杂萘基)甲基]苯甲酸的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101821242A (zh) * 2007-10-17 2010-09-01 库多斯药物有限公司 4-[3-(4-环丙烷羰基-哌嗪-1-羰基)-4-氟-苄基]-2h-酞嗪-1-酮

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1186606T4 (da) 1995-11-17 2011-12-05 Biotechnolog Forschung Gmbh Epothilonderivater, deres fremstilling og anvendelse
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
CN1345334A (zh) 1999-01-29 2002-04-17 伊姆克罗尼系统公司 对kdr特异的抗体及其应用
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
PL223343B1 (pl) 2000-10-30 2016-10-31 Kudos Pharm Ltd Zastosowanie związku, kompozycja farmaceutyczna zawierająca związek oraz pochodne ftalazynonowe
RU2292337C2 (ru) 2002-02-19 2007-01-27 Оно Фармасьютикал Ко., Лтд. Конденсированные производные пиридазина и лекарственные препараты, содержащие данные соединения в качестве активного ингредиента
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
BRPI0408284B8 (pt) * 2003-03-12 2021-05-25 Kudos Pharm Ltd compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos
CA2577191A1 (en) * 2004-08-26 2006-03-02 Kudos Pharmaceuticals Limited 4-heteroarylmethyl substituted phthalazinone derivatives
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
EP2049124A4 (en) 2006-07-20 2010-02-10 Merck & Co Inc PHOSPHOR DERIVATIVES AS HISTONDEACETYLASE HEMMER
DK2120579T3 (da) 2006-12-28 2014-02-03 Abbvie Inc Inhibitorer af poly(ADP-ripose)polymerase
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
US20080280910A1 (en) 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
ES2524787T3 (es) 2007-11-15 2014-12-12 Msd Italia S.R.L. Derivados de piridazinona como inhibidores de PARP
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
PT2300013T (pt) * 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
CN102459258B (zh) * 2009-06-05 2015-11-25 赛福伦公司 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途
SG177451A1 (en) 2009-07-02 2012-02-28 Newgen Therapeutics Inc Phosphorus containing quinazoline compounds and methods of use
EP2714703B1 (en) 2011-05-31 2021-03-10 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101821242A (zh) * 2007-10-17 2010-09-01 库多斯药物有限公司 4-[3-(4-环丙烷羰基-哌嗪-1-羰基)-4-氟-苄基]-2h-酞嗪-1-酮

Also Published As

Publication number Publication date
US20230027257A1 (en) 2023-01-26
EP2714703A4 (en) 2014-12-31
US20140221314A1 (en) 2014-08-07
JP2014516989A (ja) 2014-07-17
JP5960253B2 (ja) 2016-08-02
TW201311713A (zh) 2013-03-16
EP2714703B1 (en) 2021-03-10
CN103717609A (zh) 2014-04-09
US20200299315A1 (en) 2020-09-24
EP2714703A1 (en) 2014-04-09
ES2871052T3 (es) 2021-10-28
EP3925962A1 (en) 2021-12-22
US11248013B2 (en) 2022-02-15
CA2875025C (en) 2021-08-03
US20170057984A1 (en) 2017-03-02
WO2012166983A1 (en) 2012-12-06
US20180094010A1 (en) 2018-04-05
CA2875025A1 (en) 2012-12-06
TWI577693B (zh) 2017-04-11

Similar Documents

Publication Publication Date Title
CN103717609B (zh) 聚(adp-核糖)聚合酶的三环抑制剂
JP2022189853A (ja) ｍｅｎｉｎ－ＭＬＬ相互作用の阻害剤
ES2550677T3 (es) Triazolopiridinas sustituidas y su uso como inhibidores de TTK
CN111201223A (zh) SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
WO2023050007A1 (en) N-(5-substituted-[(1,3,4-thiadiazolyl) or (thiazolyl)])(substituted)carboxamide compounds and use thereof for inhibiting human polymerase theta
WO2023174329A1 (en) Heteroaromatic compounds as pkmyt1 inhibitors and use thereof
KR102642063B1 (ko) 칼슘 채널 억제제
US12508263B2 (en) Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof
EP3030241A1 (en) Inhibitors of ack1/tnk2 tyrosine kinase
CN120225520A (zh) 化合物和其用途
CN118055933A (zh) 选择性parp1抑制剂及其应用
CN113906040A (zh) 用于治疗癌症的化合物
KR20260019517A (ko) 3,4-디히드로프탈라진-1(2h)-온 유도체, 및 이의 제조 방법 및 이의 용도
WO2017097113A1 (zh) 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
US12612425B2 (en) Tricyclic inhibitors of poly(ADP-ribose)polymerase
CN115960109B (zh) 稠环类shp2磷酸酶抑制剂的制备及其应用
US20230212174A1 (en) Pyrrolo[2,1-f][1,2,4]triazine derivative and use thereof
TW201326170A (zh) 經取代之三唑并吡啶
HK40029610B (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant